ReviewBiomedicines2021
High-Density Lipoprotein Subfractions: Much Ado about Nothing or Clinically Important?
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Review
- Associations Between High-Density Lipoprotein Subfraction Profiles and Heart Rate Response Following Submaximal Exercise.Biology · 2026Article
- The Effect of Iatrogenic Hypothyroidism on Lipoprotein Subfractions and Markers of HDL Function in Patients with Differentiated Thyroid Carcinoma.Life (Basel, Switzerland) · 2026Article
- Dose‑dependent association of smoking exposure with HDL subfraction cholesterol content.Scientific reports · 2026Article
- High Density Lipoprotein Assessment Revisited: A Review of Foundational Understanding and Recent Developments in Function, Particle Size, and Cardiometabolic Impact.Current atherosclerosis reports · 2026Review
- Mechanisms of high-density lipoprotein in regulating blood-brain barrier function: insights and implications.Fluids and barriers of the CNS · 2025Review
- βeta-2 glycoprotein I is a novel regulator of Apolipoprotein E containing HDL particles in females.Biology of sex differences · 2025Article
- Defective lymphatic vasculature in obesity.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- Association between HDL-cholesterol subfractions and the risk of major adverse cardiac and cerebrovascular events in patients with acute myocardial infarction: a single-center retrospective observational study.Frontiers in nutrition · 2025Article
- Alterations of lipoprotein subfractions in GH-deficient adults.Frontiers in endocrinology · 2025Article
- Association between HDL-C and intensive blood pressure control in patients with hypertension: A post-hoc analysis of SPRINT.Journal of clinical hypertension (Greenwich, Conn.) · 2024Article
- HDL Levels as a Novel Predictor of Long-Term Adverse Outcomes in Patients with Heart Failure: A Retrospective Cohort Study.Journal of inflammation research · 2024Article
- A decreased level of high-density lipoprotein is a possible risk factor for type 2 diabetes mellitus: A review.Health science reports · 2023Article
- Association of HDL Subfraction Profile with the Progression of Insulin Resistance.International journal of molecular sciences · 2023Article
- High HDL (High-Density Lipoprotein) Cholesterol Increases Cardiovascular Risk in Hypertensive Patients.Hypertension (Dallas, Tex. : 1979) · 2022Article
- Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?Lipids in health and disease · 2022Review
- High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad, and the Future II.Biomedicines · 2022Article
- Association between Lipoprotein Subfractions, Hemostatic Potentials, and Coronary Atherosclerosis.Disease markers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-density lipoproteins (HDL) are a heterogenous group of plasma molecules with a large variety in composition. There is a wide specter in lipid content and the number of different proteins that has been associated with HDL is approaching 100. Given this heterogeneity and the fact that the total amount of HDL is inversely related to the risk of coronary heart disease (CHD), there has been increasing interest in the function of specific HDL subgroups and in what way measuring and quantifying these subgroups could be of clinical importance in determining individual CHD risk. If certain subgroups appear to be more protective than others, it may also in the future be possible to pharmacologically increase beneficial and decrease harmful subgroups in order to reduce CHD risk. In this review we give a short historical perspective, summarize some of the recent clinical findings regarding HDL subclassifications and discuss why such classification may or may not be of clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.